Your AI-Trained Oncology Knowledge Connection!
Ruben Mesa, MD, director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, gives advice on using the JAK inhibitors ruxolitinib and fedratinib in the community setting for patients with intermediate-risk myelofibrosis.<br />
Ovarian Cancer
Kanti R. Rai, MD, professor of medicine, Northwell Health and Zucker School of Medicine at Hofstra University, explains the importance of attention to age when treating patients with chronic lymphocytic leukemia, which is a typically elderly patient population.
Follicular Lymphoma: Treating Early Progressors
Thomas Marron, MD, discusses the rationale for investigating immunotherapy discontinuation in patients with melanoma.
